國家衛生研究院 NHRI:Item 3990099045/13019
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 912353      線上人數 : 1174
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13019


    題名: Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and liver cirrhosis
    作者: Yen, FS;Wei, JC;Chiu, LT;Hsu, CC;Hou, MC;Hwu, CM
    貢獻者: Institute of Population Health Sciences
    摘要: BACKGROUND& AIMS: Type 2 diabetes mellitus (T2DM) management in patients with liver cirrhosis is complicated. No clinical trials have investigated appropriate antidiabetic drug use in these patients. This study compared the risks of all-cause mortality, major adverse cardiovascular events (MACE), and hepatic outcomes between patients with T2DM and cirrhosis using and not using thiazolidinedione (TZD). METHODS: We selected 1,705 propensity score-matched TZD users and nonusers from a Taiwan National Health Insurance Research Database cohort of T2DM patients with compensated cirrhosis between January 1, 2000, and December 31, 2012 and followed them until December 31, 2013. Cox proportional hazards models with robust sandwich standard error estimates were used to assess risks of investigated outcomes for TZD users. RESULTS: MACE incidence rates during follow-up were 2.14 and 1.30 per 100 patient-years for TZD users and nonusers, respectively (adjusted hazard ratio [aHR] 1.70; 95% confidence interval [CI], 1.32-2.19). On the basis of TZD use, the aHRs (95% CIs) for stroke, ischemic heart disease, and heart failure were 1.81 (1.28-2.55), 1.59 (1.03-2.44), and 2.09 (1.22-3.60), respectively. Compared with TZD nonusers, rosiglitazone users had significantly higher aHR [1.67 (1.26-2.20)] and pioglitazone users had no significant difference of aHR [1.12 (0.90-1.64)]. All-cause mortality, hepatocellular carcinoma, decompensated cirrhosis, and hepatic failure risks did not differ significantly between TZD users and nonusers. CONCLUSIONS: Compared with nonuser, TZD users demonstrated significantly higher MACE risks. Therefore, the risks of cardiovascular complications should be considered when prescribing TZDs to patients with T2DM and cirrhosis.
    日期: 2021-01
    關聯: Liver International. 2021 Jan;41(1):110-122.
    Link to: http://dx.doi.org/10.1111/liv.14714
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000588198300001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85096654158
    顯示於類別:[許志成] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB33124143.pdf15922KbAdobe PDF258檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋